Distinguished in Ovarian Carcinosarcoma

Dr. June Y. Hou

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Trustees Of Columbia University In The City Of New York
51 W 51st St, Fl 3 Suite 360, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Ovarian Carcinosarcoma
Trustees Of Columbia University In The City Of New York
51 W 51st St, Fl 3 Suite 360, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

June Hou is a Gynecologic Oncologist and an Oncologist in New York, New York. Dr. Hou is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Hysterectomy, and Oophorectomy.

Her clinical research consists of co-authoring 146 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
51 W 51st St, Fl 3 Suite 360, New York, NY 10019

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 03, 2025
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: Tisotumab vedotin
Study Phase: Phase 2
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: March 09, 2021
Intervention Type: Drug
Study Phase: Phase 1
An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used In Combination With Paclitaxel In Patients With Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer
An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used In Combination With Paclitaxel In Patients With Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer
Enrollment Status: Unknown
Publish Date: March 18, 2020
Intervention Type: Drug
Study Drug: SPL-108
Study Phase: Phase 1
A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma
A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma
Enrollment Status: Unknown
Publish Date: January 24, 2017
Intervention Type: Drug
Study Drug: Sodium Cridanimod
Study Phase: Phase 2
View 7 Less Clinical Trials

146 Total Publications

Use and outcomes of hormonal therapy for advanced-stage, low-grade serous ovarian cancer.
Use and outcomes of hormonal therapy for advanced-stage, low-grade serous ovarian cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: April 09, 2025
Similar Doctors
Distinguished in Ovarian Carcinosarcoma
Dr. Whitfield B. Growdon
Gynecologic Oncology | Obstetrics and Gynecology
Distinguished in Ovarian Carcinosarcoma
Dr. Whitfield B. Growdon
Gynecologic Oncology | Obstetrics and Gynecology

New York University

240 E 38th St, 
New York, NY 
 (1.0 miles away)
212-263-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Whitfield Growdon is a Gynecologic Oncologist and an Obstetrics and Gynecologist in New York, New York. Dr. Growdon is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Vulvar Cancer, Hysterectomy, and Oophorectomy.

Elite in Ovarian Carcinosarcoma
Dr. Joan R. Tymon-Rosario
Obstetrics and Gynecology | Oncology
Elite in Ovarian Carcinosarcoma
Dr. Joan R. Tymon-Rosario
Obstetrics and Gynecology | Oncology

North Shore-Lij Medical PC

27005 76th Ave, 
New Hyde Park, NY 
 (14.3 miles away)
718-470-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joan Tymon-Rosario is an Obstetrics and Gynecologist and an Oncologist in New Hyde Park, New York. Dr. Tymon-Rosario is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Hysterectomy, and Oophorectomy.

Distinguished in Ovarian Carcinosarcoma
Dr. Andrew W. Menzin
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Ovarian Carcinosarcoma
Dr. Andrew W. Menzin
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

North Shore-Lij Medical PC

27005 76th Ave, 
New Hyde Park, NY 
 (14.3 miles away)
718-470-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Menzin is a Gynecologic Oncologist and an Oncologist in New Hyde Park, New York. Dr. Menzin is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hernia Surgery, and Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hou's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile